ATX-304 for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

ATX-304 for Health & Longevity

Created on 08/27/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

An experimental oral medication that switches on the enzyme cells use to sense low fuel — the same switch thrown by hard exercise and fasting. Two short studies lowered fasting blood sugar and blood pressure, reduced liver and organ fat, and raised resting energy burn. No result repeated, longest use four months, all human data company-funded, no verifiable retail source. (Full Review)

Protocol

Studied doses
1,000 mg or 400 mg once daily
1,000 mg oral suspension for 28 days (phase IIa); 400 mg oral formulation for 8 weeks plus an 8-week open-label extension (phase 1b)
Time of day
Once daily, morning
Both trials used once-daily morning dosing; the long half-life makes timing largely irrelevant to exposure, so consistency of timing matters more than the hour chosen
Single versus split dosing
Single daily dose
The compound accumulates to steady state over two weeks, so splitting the dose offers no exposure advantage and has never been tested
Time to effect
Fasting glucose
Days 21–28
Steady-state blood levels took 14 days; nothing meaningful should be expected inside two weeks
Blood pressure
By day 28
Systolic and diastolic pressure fell in the treated group over the 28-day trial
Fat, lipid and metabolic-rate changes
8 weeks
Liver and visceral fat, triglycerides, adiponectin and resting metabolic rate were measured at eight weeks

Benefits

Contraindications
  • Anyone outside a supervised clinical trial
  • Pregnancy and breastfeeding
  • People under 18 years
  • Type 1 diabetes, or type 2 diabetes on insulin or sulfonylureas without dose adjustment
  • Baseline systolic blood pressure below 100 mmHg, or symptomatic orthostatic hypotension
  • Established cardiomyopathy, heart failure of New York Heart Association Class III–IV, or a known PRKAG2 variant
  • Liver impairment of Child-Pugh Class B or C
  • Kidney impairment with eGFR below 45 mL/min/1.73 m²
  • Uncontrolled overactive thyroid, or any condition impairing temperature regulation
  • Recent myocardial infarction within 90 days, or unstable angina
  • Other mitochondrial uncouplers and thermogenic agents (2,4-dinitrophenol, high-dose ephedrine or synephrine combinations)
    •
Key Interactions
  • Metformin (prescription)
  • Insulin and sulfonylureas (prescription, e.g. glipizide, glimepiride, gliclazide)
  • Antihypertensives (prescription, e.g. lisinopril, losartan, amlodipine)
  • GLP-1 receptor agonists (prescription, e.g. semaglutide, tirzepatide)
  • Diuretics (over-the-counter and prescription, e.g. hydrochlorothiazide, caffeine-based products)
  • Non-steroidal anti-inflammatory drugs (over-the-counter, e.g. ibuprofen, naproxen)
  • AMPK-activating supplements (berberine, Gynostemma pentaphyllum, alpha-lipoic acid, metformin-mimetic extracts)
  • Blood-pressure-lowering supplements (beetroot or nitrate concentrates, magnesium at high intake, garlic extract, omega-3 fatty acids)
  • Heat exposure and endurance training
    •

Risk & Side Effects

  • Medium: Blood pressure lowering and hypotension in combination; mild treatment-emergent adverse events
  • Low: Hypoglycemia in combination with glucose-lowering drugs; thermogenic and cardiovascular effects of uncoupling
  • Speculative: Cardiac glycogen accumulation and remodelling; blunted high-intensity performance; reproductive and developmental toxicity; tumour growth support under sustained AMPK activation; adulterated or misidentified gray-market material

Monitoring

Marker Target Why
Fasting plasma glucose 4.4–5.0 mM (79–90 mg/dL) Primary human-validated effect
Fasting insulin 2–5 mIU/L Detects insulin resistance before glucose moves
HOMA-IR Below 1.0 The endpoint that improved in the phase IIa trial
HbA1c 4.8–5.2% Three-month glucose average, filters daily noise
Triglycerides Below 0.9 mM (80 mg/dL) Fell significantly in the phase 1b study
Adiponectin Above 10 µg/mL Rose significantly in the phase 1b study
ALT Below 25 U/L (men), below 20 U/L (women) Liver stress and fat-driven injury
Liver fat fraction Below 3% The imaging endpoint that changed in humans
Creatinine and eGFR eGFR above 90 mL/min/1.73 m² Kidney safety, and the animal-model claim
Blood pressure (home, seated and standing) 110–120 / 70–78 mmHg The clearest human effect and the clearest interaction risk
Resting heart rate 50–65 bpm Detects thermogenic drift from uncoupling
Core body temperature Within 0.3 °C of personal baseline The safety signal the drug class is judged on
Creatine kinase Below 200 U/L Muscle integrity, given the muscle-sparing claim
Lactate (fasting) Below 1.5 mM Guards against the uncoupling failure mode
Body composition No fat-free mass loss Distinguishes fat loss from muscle loss

Cadence: Baseline before the first dose, including two weeks of home blood-pressure readings and an electrocardiogram. Blood pressure daily for the first four weeks, then weekly; blood panels at 4 weeks, 12 weeks, then every 3 to 6 months; imaging-based body composition and liver fat at 6 and 12 months. Nothing judged before day 14.

Qualitative Assessment

  • Standing tolerance — lightheadedness on rising is the earliest sign of the additive blood-pressure effect
  • Heat tolerance — new discomfort in saunas, hot showers or warm weather
  • Endurance session perceived effort at a fixed heart rate
  • Recovery from heavy resistance training, and whether session loads hold
  • Energy stability across the day, and appetite change
  • Sleep onset latency and night-time thermal comfort
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.